抗体-药物结合物（ADC）由理想的单克隆抗体、活性细胞毒性药物和合适的连接剂组成。抗体和细胞毒性药物之间的适当连接物提供特异性桥，从而帮助抗体选择性地将细胞毒性药物递送至肿瘤细胞，并在肿瘤部位精确地释放细胞毒性药物
2-((1-Phenyl-2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)oxy)tetrahydro-2H-pyran
tert-Butyl 5,8,11,14-tetraoxa-2-azaheptadecan-17-oate
2-((1-Phenyl-2,5,8,11,14-pentaoxahexadecan-16-yl)oxy)tetrahydro-2H-pyran
4-((S)-2-((S)-2-Amino-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate
2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-ol
2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azatricosan-23-oic acid
(14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-Chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-methyl-N-(3-(methyldisulfaneyl)propanoyl)-L-alaninate
(14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-Chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(4-mercapto-4-methylpentanoyl)-N-methyl-L-alaninate
MC-Val-Cit-PAB-MMAF
2,5-Dioxopyrrolidin-1-yl 4-((3-((3-(((S)-1-(((14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl)oxy)-1-oxopropan-2-yl)(methyl)amino)-3-oxopropyl)thio)-2,5-dioxopyrrolidin-1-yl)methyl)cyclohexane-1-carboxylate
Methyl 1-hydroxy-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oate
2,5,8,11-Tetraoxatridecan-13-yl 4-methylbenzenesulfonate
N-(2-(2-(2-(2-(4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-oic acid
3-Oxo-2,6,9,12,15,18-hexaoxahenicosan-21-oic acid
tert-Butyl 14-(tosyloxy)-3,6,9,12-tetraoxatetradecan-1-oate
Methyl 14-hydroxy-3,6,9,12-tetraoxatetradecan-1-oate
tert-Butyl 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxycarbamate
tert-Butyl 20-hydroxy-3,6,9,12,15,18-hexaoxaicosanoate
(2S,4R)-N-((S)-2-(tert-Butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecan-1-oyl)-4-hydroxy-1-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
(2S,4R)-N-((S)-2-(tert-Butyl)-24-chloro-4-oxo-6,9,12,15,18-pentaoxa-3-azatetracosanoyl)-4-hydroxy-1-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
tert-Butyl 1-(4-formylphenyl)-1-oxo-5,8,11,14-tetraoxa-2-azaheptadecan-17-oate
11-Azido-3,6,9-trioxaundecanol
14-Azido-3,6,9,12-tetraoxatetradecan-1-amine
Triethylene Glycol Mono(2-propynyl) Ether
3,6,9,12,15,18,21,24-Octaoxahexacosane-1,26-diyl bis(4-methylbenzenesulfonate)
21-Chloro-3,6,9,12,15-pentaoxahenicosan-1-amine hydrochloride
1,11-Bis(maleimido)-3,6,9-trioxaundecane
2,5,8,11,14-Pentaoxaheptadec-16-yne
